On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

Acumen Pharmaceuticals (United States)

InstitutionResearch output, impact & collaborations

Acumen Pharmaceuticals (United States) is a institution indexed in ScholarIQ from OpenAlex.

What is known about Acumen Pharmaceuticals (United States)?

ScholarIQrecord summary

Acumen Pharmaceuticals (United States) is a research organisation in Livermore, United States. OpenAlex records 105 works and 25,986 citations for it. 2 researchers list it as their most recent affiliation.

How many works does Acumen Pharmaceuticals (United States) have?

ScholarIQindexed works

Acumen Pharmaceuticals (United States) has 105 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Acumen Pharmaceuticals (United States) →

How many citations does Acumen Pharmaceuticals (United States) have?

ScholarIQcitation count

Acumen Pharmaceuticals (United States) has 25,986 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for Acumen Pharmaceuticals (United States) →

How many researchers are at Acumen Pharmaceuticals (United States)?

ScholarIQresearcher count

Acumen Pharmaceuticals (United States) has 2 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at Acumen Pharmaceuticals (United States)?

ScholarIQavg h-index

Acumen Pharmaceuticals (United States) has an average h-index of 50 in OpenAlex.

Open the OpenAlex record →

What is the ROR of Acumen Pharmaceuticals (United States)?

ScholarIQror

The ROR for Acumen Pharmaceuticals (United States) is on the source record.

Open the ROR →

What is the OpenAlex record for Acumen Pharmaceuticals (United States)?

ScholarIQopenalex

The OpenAlex for Acumen Pharmaceuticals (United States) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind Acumen Pharmaceuticals (United States)?

ScholarIQtop researchers by citations

Eric Siemers · Alzheimer's disease research and treatments

259 works37,505 citations

Grant A. Krafft · Alzheimer's disease research and treatments

112 works16,173 citations

What are the most-cited papers on Acumen Pharmaceuticals (United States)?

ScholarIQmost cited works

Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Reisa A. Sperling, Paul Aisen, Laurel Beckett, David A. Bennett, Suzanne Craft, Anne M. Fagan, Takeshi Iwatsubo, Clifford R. Jack, Jeffrey Kaye, Thomas J. Montine, Denise C. Park, Eric M. Reiman, Christopher C. Rowe, Eric Siemers, Yaakov Stern, Kristine Yaffe, María C. Carrillo, Bill Thies, Marcelle Morrison‐Bogorad, Molly V. Wagster, Creighton H. Phelps

Alzheimer s & Dementia. 20117,190 CitationsOPEN ACCESS

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

Clifford R. Jack, J. Scott Andrews, Thomas G. Beach, Teresa Buracchio, Billy Dunn, Ana Graf, Oskar Hansson, Carole Ho, William J. Jagust, Eric McDade, José Luís Molinuevo, Ozioma C. Okonkwo, Luca Pani, Michael S. Rafii, Philip Scheltens, Eric Siemers, Heather M. Snyder, Reisa A. Sperling, Charlotte E. Teunissen, Marı́a C. Carrillo

Alzheimer s & Dementia. 20242,424 CitationsOPEN ACCESS

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

Rachelle S. Doody, Ronald G. Thomas, Martin R. Farlow, Takeshi Iwatsubo, Bruno Vellas, Steven Joffe, Karl Kieburtz, Rema Raman, Xiaoying Sun, Paul Aisen, Eric Siemers, Hong Liu‐Seifert, Richard C. Mohs

New England Journal of Medicine. 20141,654 CitationsOPEN ACCESS

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

Lawrence S. Honig, Bruno Vellas, Mark Woodward, Merçé Boada, Roger Bullock, Michael Borrie, Klaus Häger, Niels Andreasen, Elio Scarpini, Hong Liu‐Seifert, Michael Case, Robert A. Dean, Ann Marie Hake, Karen Sundell, Vicki Poole Hoffmann, Christopher Carlson, Rashna Khanna, Mark A. Mintun, Ronald B. DeMattos, Katherine J. Selzler, Eric Siemers

New England Journal of Medicine. 20181,062 CitationsOPEN ACCESS

Amyloid beta oligomers induce impairment of neuronal insulin receptors

Weiqin Zhao, Fernanda G. De Felice, Sara J. Fernandez, Hui Chen, Mary P. Lambert, Michael J. Quon, Grant A. Krafft, William L. Klein

The FASEB Journal. 2007590 Citations

How much of the research on Acumen Pharmaceuticals (United States) is open access?

ScholarIQopen access share

80%OPEN ACCESS

Gold

Green

20%

Hybrid

20%

Bronze

40%

Closed

20%